Latest News

Tanabe Research Laboratories and Mitsubishi Tanabe Pharma Nominate First Bispecific FynomAb® for Preclinical Development and Exercise an Option for a Second Bispecific FynomAb Program

November 21st, 2013, Switzerland and San Diego – Covagen and Tanabe Research Laboratories U.S.A, Inc. (TRL), a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed...


MIMICS Emerging Data Suggest Patency Protective Effect

Las Vegas, USA, 9 October 2013 – Data presented here yesterday during the Late Breaking Clinical Trials session at VIVA13 show that a stent with unique three dimensional helical geometry, BioMimics 3D™, developed by Veryan Medical Ltd., (Horsham, UK), a portfolio company of Seroba Kernel Life Sciences, has demonstrated safety and promising clinical performance at twelve months...


Xention and Servier Announce a €120m Cardiovascular Collaboration.

Xention and Servier announce a €120M cardiovascular collaboration to further develop a selective Kv1.5 modulator for the treatment of atrial fibrillation. October 2nd, 2013, Cambridge, UK and Suresnes, France– Xention Ltd., a portfolio company of Seroba Kernel based in Cambridge and specialising in the discovery and development of ion channel-modulating...


< back to home page